3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
70
Lymphoma, Large B-Cell, Diffuse
67
Lymphoma
66
Lymphoma, Follicular
59
Leukemia, Lymphocytic, Chronic, B-Cell
58
Lymphoma, B-Cell, Marginal Zone
30
Burkitt Lymphoma
30
Waldenstrom Macroglobulinemia
24
Lymphoma, Mantle-Cell
24
Lymphoma, B-Cell
24
Precursor Cell Lymphoblastic Leukemia-Lymphoma
22
Leukemia
19
Recurrence
17
Hodgkin Disease
12
Neoplasms
10
Lymphoma, Large-Cell, Immunoblastic
10
Multiple Myeloma
8
Leukemia, Prolymphocytic
8
Leukemia, Myeloid, Acute
8
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
7
Myelodysplastic Syndromes
7
Mycosis Fungoides
6
Lymphoma, T-Cell, Cutaneous
6
Leukemia, Hairy Cell
6
Sezary Syndrome
5
Neoplasms, Plasma Cell
5
Lymphoma, Large-Cell, Anaplastic
5
Lymphoma, Extranodal NK-T-Cell
5
Intraocular Lymphoma
5
Dendritic Cell Sarcoma, Interdigitating
5
Interventions
Fulvestrant
3
Alpelisib
3
duvelisib
2
Cetuximab
2
volagidemab
1
talazoparib
1
ruxolitinib
1
parsaclisib
1
olaparib
1
obinutuzumab
1
lorlatinib
1
encorafenib
1
dapagliflozin
1
cobimetinib
1
chiauranib
1
binimetinib
1
avelumab
1
Vemurafenib
1
SF 1126
1
Rituximab
1
NVP-BKM120
1
Drug Therapy
1
CYH33
1
Aspirin
1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Hereditary Sensory and Autonomic Neuropathies
×
Rituximab
×
Clear all
NCT02204982
2023-09-28
DYNAMO + R
SecuraBio
Phase 3
Terminated
13 enrolled
10 charts
1 FDA